| 0.4026 -0.013 (-3.2%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.22 | 1-year : | 1.84 |
| Resists | First : | 1.04 | Second : | 1.58 |
| Pivot price | 0.54  |
|||
| Supports | First : | 0.18 | Second : | 0.15 |
| MAs | MA(5) : | 0.4 |
MA(20) : | 0.45 |
| MA(100) : | 0.32 |
MA(250) : | 0.5 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 14.6 |
D(3) : | 14.6 |
| RSI | RSI(14): 48.8 |
|||
| 52-week | High : | 1.58 | Low : | 0.18 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ KZIA ] has closed above bottom band by 36.5%. Bollinger Bands are 311.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.43 - 0.43 | 0.43 - 0.44 |
| Low: | 0.38 - 0.39 | 0.39 - 0.39 |
| Close: | 0.4 - 0.4 | 0.4 - 0.41 |
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Sat, 20 Jul 2024
Kazia Therapeutics (NASDAQ:KZIA) and Organogenesis (NASDAQ:ORGO) Head to Head Review - Defense World
Fri, 12 Jul 2024
HC Wainwright Reaffirms “Buy” Rating for Kazia Therapeutics (NASDAQ:KZIA) - Defense World
Fri, 12 Jul 2024
Kazia Therapeutics’ (KZIA) “Buy” Rating Reaffirmed at HC Wainwright - American Banking and Market News
Fri, 12 Jul 2024
Kazia Therapeutics stock maintains buy rating - Investing.com
Fri, 12 Jul 2024
Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why - Yahoo Finance
Wed, 10 Jul 2024
Why Is Kazia Therapeutics Stock Trading Higher On Wednesday? - Kazia Therapeutics (NASDAQ:KZIA) - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -7 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 2.979e+007 (%) |
| Held by Institutions | 2.3436e+008 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.38 |
| Profit Margin | 0 % |
| Operating Margin | -148 % |
| Return on Assets (ttm) | 56 % |
| Return on Equity (ttm) | 737.5 % |
| Qtrly Rev. Growth | -186.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.98 |
| Qtrly Earnings Growth | -1.752e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -1.06 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 47130 |
| Forward Dividend | 26540 |
| Dividend Yield | 11706400% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|